Neurocrine Biosciences Management

Management criteria checks 2/4

Neurocrine Biosciences' CEO is Kevin Gorman, appointed in Jan 2008, has a tenure of 16.33 years. total yearly compensation is $15.75M, comprised of 6% salary and 94% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $70.78M. The average tenure of the management team and the board of directors is 6.5 years and 11.4 years respectively.

Key information

Kevin Gorman

Chief executive officer

US$15.8m

Total compensation

CEO salary percentage	6.0%
CEO tenure	16.3yrs
CEO ownership	0.5%
Management average tenure	6.5yrs
Board average tenure	11.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Gorman's remuneration changed compared to Neurocrine Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$370m
Dec 31 2023	US$16m	US$946k	US$250m
Sep 30 2023	n/a	n/a	US$191m
Jun 30 2023	n/a	n/a	US$176m
Mar 31 2023	n/a	n/a	US$64m
Dec 31 2022	US$12m	US$860k	US$155m
Sep 30 2022	n/a	n/a	US$58m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$71m
Dec 31 2021	US$14m	US$825k	US$90m
Sep 30 2021	n/a	n/a	US$445m
Jun 30 2021	n/a	n/a	US$365m
Mar 31 2021	n/a	n/a	US$402m
Dec 31 2020	US$14m	US$775k	US$407m
Sep 30 2020	n/a	n/a	US$93m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$9m	US$725k	US$37m
Sep 30 2019	n/a	n/a	US$21m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$9m	US$675k	US$21m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$8m	US$640k	-US$143m

Compensation vs Market: Kevin's total compensation ($USD15.75M) is above average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.

CEO

Kevin Gorman (65 yo)

16.3yrs

Tenure

US$15,750,812

Compensation

Dr. Kevin C. Gorman, Ph D., has been Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008 and served as its President since January 2008. Dr. Gorman is a Founder of Neurocrine Bioscie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Gorman	CEO & Director	16.3yrs	US$15.75m	0.51% $ 70.8m
Matthew Abernethy	Chief Financial Officer	6.5yrs	US$6.06m	0.031% $ 4.3m
Jude Onyia	Chief Scientific Officer	2.5yrs	US$7.22m	0.013% $ 1.8m
Kyle Gano	Chief Business Development & Strategy Officer	13.3yrs	US$5.99m	0.13% $ 18.6m
Eiry Roberts	Chief Medical Officer	6.3yrs	US$5.87m	0.024% $ 3.3m
Jane Sorensen	Head of Investor Relations	no data	no data	no data
Darin Lippoldt	Chief Legal Officer & Corporate Secretary	9.6yrs	US$4.72m	0.040% $ 5.5m
Julie Cooke	Chief Human Resources Officer	6.7yrs	no data	0.018% $ 2.5m
Eric Benevich	Chief Commercial Officer	9yrs	US$5.81m	0.041% $ 5.6m
David Boyer	Chief Corporate Affairs Officer	4.7yrs	no data	0.0049% $ 673.7k
Ingrid Delaet	Chief Regulatory Officer	1.6yrs	no data	0.0075% $ 1.0m
Christopher O'Brien	Exclusive Consultant	6.3yrs	US$3.10m	no data

6.5yrs

Average Tenure

57yo

Average Age

Experienced Management: 0K6R's management team is seasoned and experienced (6.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Gorman	CEO & Director	16.3yrs	US$15.75m	0.51% $ 70.8m
Christine Poon	Independent Director	less than a year	US$813.45k	0% $ 0
Richard Pops	Independent Director	26.1yrs	US$492.04k	0.029% $ 4.1m
Stephen Sherwin	Independent Director	25.1yrs	US$479.54k	0.022% $ 3.1m
William Rastetter	Independent Chairman of the Board	14.3yrs	US$495.04k	0.051% $ 7.1m
Gary Lyons	Independent Director	31.3yrs	US$460.11k	0.12% $ 16.1m
George Morrow	Independent Director	8.6yrs	US$479.54k	0% $ 0
Shalini Sharp	Independent Director	4.3yrs	US$497.11k	0% $ 0
Leslie Norwalk	Independent Director	4.7yrs	US$475.11k	0% $ 0
Johanna Mercier	Independent Director	3.1yrs	US$467.61k	0% $ 0

11.4yrs

Average Tenure

68yo

Average Age

Experienced Board: 0K6R's board of directors are seasoned and experienced ( 11.4 years average tenure).

Neurocrine Biosciences Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Insufficient new directors

Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's Executive Management Team as Chief Regulatory Officer Effective October 1, 2022

Neurocrine Biosciences, Inc., Annual General Meeting, May 18, 2022

Recent updates

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

First quarter 2024 earnings released: EPS: US$0.43 (vs US$0.79 loss in 1Q 2023)

Insufficient new directors

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

New minor risk - Shareholder dilution

Full year 2023 earnings released: EPS: US$2.56 (vs US$1.61 in FY 2022)

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

New minor risk - Shareholder dilution

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.85 (vs US$0.71 in 3Q 2022)

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.98 (vs US$0.18 loss in 2Q 2022)

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.15 profit in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.61 (vs US$0.95 in FY 2021)

Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

Third quarter 2022 earnings released: EPS: US$0.71 (vs US$0.24 in 3Q 2021)

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

Neurocrine Biosciences, Inc. Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022

Neurocrine Biosciences, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's Executive Management Team as Chief Regulatory Officer Effective October 1, 2022

Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

Neurocrine Biosciences, Inc. Announces to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians At 2022 MDS International Congress

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) agreed to acquire Diurnal Group plc (AIM:DNL) for £46.8 million.

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of Fiscal 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 profit in 2Q 2021)

Neurocrine Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Neurocrine Biosciences, Inc. Presents Data on Sleep Disturbances and Off Time in Patients with Parkinson's Disease and Motor Fluctuations At Sleep 2022

First quarter 2022 earnings released: EPS: US$0.15 (vs US$0.34 in 1Q 2021)

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2022

Neurocrine Biosciences, Inc. to Report Q1, 2022 Results on May 04, 2022

Neurocrine Biosciences, Inc., Annual General Meeting, May 18, 2022

Neurocrine Biosciences Presents Phase 3 Data for Kinect-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease At AAN 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Neurocrine Biosciences Announces Positive Phase 3 Data

Third quarter 2021 earnings released: EPS US$0.24 (vs US$0.62 loss in 3Q 2020)

Neurocrine Biosciences, Inc. to Present New INGREZZA (Valbenazine) and ONGENTYS (Opicapone) Data at the MDS Virtual Congress 2021

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.86 in 2Q 2020)

Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) dropped from Russell 1000 Growth-Defensive Index

First quarter 2021 earnings released: EPS US$0.34 (vs US$0.40 in 1Q 2020)